https://orcid.org/0000-0002-9412-9424
References
- Ashford MB, England RM, Akhtar N. Highway to success-developing advanced polymeric therapeutics. Adv. Ther. 2021;4: Article 2000285. doi: 10.1002/adtp.202000285
- Chandra K, Dutta S, Kolya H, Kang C-W. Structural aspect of hydroxyethyl starch anticancer drug conjugates as state-of-the-art drug carriers. Scient. Pharm. 2023;91: Article 32. doi: 10.3390/scipharm91030032
- Wang H, Hu H, Yang H, Li Z. Hydroxyethyl starch based smart nanomedicine. RSC Adv. 2021;11:3226–3240. doi: 10.1039/D0RA09663F
- Paleos CM, Sideratou Z, Tsiourvas D. Drug delivery systems based on hydroxyethyl starch. Bioconjug. Chem. 2017;28:1611–1624. doi: 10.1021/acs.bioconjchem.7b00186
- Walker AM, Xiao Y, Johnston CR, Rival DE. The viscous characterization of hydroxyethyl starch (HES) plasma volume expanders in a non-Newtonian blood analog. Biorheol. 2013;50:177–190. doi: 10.3233/BIR-130635
- Klemm E, Bepperling F, Burschka MA, Mösges R. Study Group. Hemodilution therapy with hydroxyethyl starch solution (130/0.4) in unilateral idiopathic sudden sensorineural hearing loss: a dose-finding, double-blind, placebo-controlled, international multicentre trial with 210 patients. Otol. Neurotol. 2007;28:157–170. doi: 10.1097/01.mao.0000231502.54157 .ad.
- Sarder R, Piner E, Rios DC et al. Copolymers of starch, a sustainable template for biomedical applications: a review. Carbohyd. Polym. 2022;278: Article 118973. doi: 10.1016/j.carbpol.2021.118973
- Liebner R, Meyer M, Hey T, Winter G, Besheer A. Head-to-head comparison of the formulation and stability of concentrated solutions of HESylated versus PEGylated anakinra. J. Pharm. Sci. 2015;104:515–526. doi: 10.1002/jps.24253
- Noga M, Edinger D, Wagner E, Winter G, Besheer A. Stability, and activity of hydroxyethyl starch-coated polyplexes in frozen solutions or lyophilizates. Int. J. Pharm. 2014;469:50–58. doi: 10.1016/j.ijpharm.2014.04.020
- Liebner R, Meyer M, Hey T, Winter G, Besheer A. Head-to-head comparison of the formulation and stability of concentrated solutions of HESylated versus PEGylated anakinra. J. Pharm. Sci. 2015;104:515–526.doi: 10.1002/jps.24253
- Stolzing A, Naaldijk Y, Fedorova V, Sethe S. Hydroxyethyl starch in cryopreservation – mechanisms, benefits, and problems. Transfus. Apher. Sci. 2012;46:137–147.doi: 10.1016/j.transci.2012.01.007
- Luo Q, Wang P, Miao Y, He H, Tang X. A novel 5-fluorouracil prodrug using hydroxyethyl starch as a macromolecular carrier for sustained release. Carbohyd. Polym. 2012;87:2642–2647. doi: 10.1016/j.carbpol.2011.11.039
- Li G, Li Y, Tang Y et al. Hydroxyethyl starch conjugates for improving the stability, pharmacokinetic behaviour, and antitumor activity of 10-hydroxy camptothecin. Int. J. Pharm. 2014;471:234–244.doi: 10.1016/j.ijpharm.2014.05.038
- Li G, Zhao M, Zhao L. Lysine-mediated hydroxyethyl starch-10-hydroxy camptothecin micelles for the treatment of liver cancer. Drug Deliv. 2020;27:519–529.doi: 10.1080/10717544.2020.1745329
- Goszczyński TM, Filip-Psurska B, Kempińska K, Wietrzyk J, Boratyński J. Hydroxyethyl starch as an effective methotrexate carrier in anticancer therapy. Pharmacol Res. Perspect. 2014;2: Article e00047. doi: 10.1002/prp2.47
- Zhu Y, Yao X, Chen X, Chen L. pH-sensitive hydroxyethyl starch-doxorubicin conjugates as antitumor prodrugs with enhanced anticancer efficacy. J. Appl. Polymer Sci. 2015;132: Article 42778. doi: 10.1002/app.42778
- Hu H, Li Y, Zhou Q et al. Redox-sensitive hydroxyethyl starch-doxorubicin conjugate for tumor targeted drug delivery. ACS Appl. Mater Interf. 2016;8:30833–30844. doi: 10.1021/acsami.6b11932
- Li Y, Hu H, Zhou Q et al. α-amylase- and redox-responsive nanoparticles for tumor-targeted drug delivery. ACS Appl. Mater. Interf. 2017;9:19215–19230. doi: 10.1021/acsami.7b04066
- Tan R, Tian D, Liu J, Wang C, Wan Y. Doxorubicin-bound hydroxyethyl starch conjugate nanoparticles with pH/redox responsive linkage for enhancing antitumor therapy. Int. J. Nanomed. 2021;16:4527–4544. doi: 10.2147/IJN.S314705
- Yu C, Zhou Q, Xiao F et al. Enhancing doxorubicin delivery toward tumor by hydroxyethyl starch-g-polylactide partner nanocarriers. ACS Appl. Mater. Interf. 2017;9:10481–10493.doi: 10.1021/acsami.7b00048
- Xu C, Li S, Chen J et al. Doxorubicin and erastin co-loaded hydroxyethyl starch-polycaprolactone nanoparticles for synergistic cancer therapy. J. Control Rel. 2023;356:256–271. doi: 10.1016/j.jconrel.2023.03.001